# Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

> **NCT07139743** · PHASE1 · RECRUITING · sponsor: **Autolus Limited** · enrollment: 18 (estimated)

## Conditions studied

- Progressive Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Obecabtagene autoleucel (obe-cel)

## Key facts

- **NCT ID:** NCT07139743
- **Lead sponsor:** Autolus Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-04
- **Primary completion:** 2029-08-15
- **Final completion:** 2029-08-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07139743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07139743, "Obe-cel in Refractory Progressive Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07139743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*